Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lorcaserin HCl
Therapeutic Area: Neurology Product Name: E2023
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
In addition to the MOMENTUM 1 Study, Eisai is continuing the lorcaserin expanded access program, also known as the MOMENTUM 2 Study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ban2401
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The clinical study design of the newly initiated Phase III clinical study evaluating BAN2401 for preclinical Alzheimer’s disease (AD) patients will be presented orally.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ban2401
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Satralizumab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Details:
Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rovatirelin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
Details:
In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
